Johnson & Johnson

NYSE:JNJ   1:11:33 PM EDT
179.17
+2.19 (+1.24%)
Products

Janssen - FDA Approves Expanded Pad Indication For Xarelto Plus Aspirin To Include Patients After LER Due To Symptomatic Pad

Published: 08/24/2021 15:20 GMT
Johnson & Johnson (JNJ) - FDA Approves Expanded Peripheral Artery Disease (pad) Indication for Xarelto® (rivaroxaban) Plus Aspirin to Include Patients After Lower-extremity Revascularization (ler) Due to Symptomatic Pad.
Janssen - FDA Approves Expanded Pad Indication for Xarelto Plus Aspirin to Include Patients After Ler Due to Symptomatic Pad.